AACR
TEVA icon

ACR Alpine Capital Research’s Teva Pharmaceuticals TEVA Stock Holding History

ACR Alpine Capital Research’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-6,700
Closed -$351K – 27
2014
Q2 		$351K Hold
6,700
– – 0.05% 19
2014
Q1 		$354K Buy
+6,700
New +$310K 0.06% 18

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACR Alpine Capital Research's TEVA Position: Q3 2014 in Review

ACR Alpine Capital Research sold out of Teva Pharmaceuticals (TEVA) in Q3 2014, closing a stake of 6,700 shares — an estimated $351K sold.

ACR Alpine Capital Research first reported a position in TEVA in Q1 2014 and held it in 2 quarters. The position peaked at $354K in Q1 2014. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • ACR Alpine Capital Research reported no remaining Teva Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • ACR Alpine Capital Research sold 6,700 Teva Pharmaceuticals shares in Q3 2014, an estimated $351K.
  • ACR Alpine Capital Research first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • ACR Alpine Capital Research's Teva Pharmaceuticals position peaked at $354K in Q1 2014.
  • 772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on ACR Alpine Capital Research's 13F filing for Q3 2014, filed 12 Nov 2014.